Table 4.

GEE regression analysis for the number of oocytes retrieved.

Independent variable	POSEIDON group 1			POSEIDON group 2			POSEIDON group 3			POSEIDON group 4
	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value
GH supplementation
Non-GH	_	_		_	_		_	_		_	_
GH	1.47	1.36–1.59	<0.001*	1.31	1.15–1.49	<0.001*	1.17	1.00–1.36	0.054	1.04	0.89–1.20	0.637
Age	1.00	0.99–1.02	0.624	1.00	0.98–1.02	0.838	1.01	0.98–1.05	0.355	1.00	0.98–1.03	0.885
BMI	0.98	0.97–1.00	0.033*	0.99	0.97–1.01	0.231	1.01	0.99–1.01	0.458	1.00	0.97–1.02	0.766
AMH	1.04	1.02–1.07	0.001*	0.96	0.92–1.00	0.062	1.68	1.24–2.28	0.001*	1.60	1.24–2.05	<0.001*
FSH	0.99	0.96–1.03	0.741	0.95	0.92–0.99	0.005*	0.98	0.95–1.01	0.124	0.97	0.95–0.99	0.013*
AFC	1.01	1.00–1.02	0.075	1.03	1.01–1.05	0.001*	1.02	0.98–1.06	0.352	1.01	0.98–1.05	0.381
COH protocol
GnRH antagonist	_	_		_	_		_	_		_	_
GnRH agonist long	1.20	1.08–1.32	<0.001*	1.14	0.97–1.33	0.114	1.12	0.92–1.37	0.261	1.31	1.06–1.62	0.012*
GnRH agonist ultra-long	1.05	0.91–1.22	0.490	1.31	1.06–1.62	0.014*	0.84	0.64–1.10	0.209	1.16	0.89–1.51	0.268
GnRH agonist short	1.09	0.96–1.24	0.190	1.23	1.05–1.45	0.010*	0.91	0.75–1.11	0.353	1.09	0.91–1.29	0.355
Duration of Gn	1.00	0.97–1.02	0.740	1.02	0.98–1.07	0.292	1.05	1.00–1.10	0.033*	1.04	0.99–1.09	0.121
Gn dose (per 100 IU)	1.01	1.00–1.01	0.006*	1.00	0.99–1.01	0.777	1.00	0.99–1.01	0.735	1.00	1.00–1.00	0.574

GH, growth hormone; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin.

In bold: The values associated with GH.

*indicates statistical significances of p < 0.05.